Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vedolizumab Outcomes in Real-World Biologic Ulcerative Colitis and Crohn's Disease Patients

Trial Profile

Vedolizumab Outcomes in Real-World Biologic Ulcerative Colitis and Crohn's Disease Patients

Not yet recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms EVOLVE-IBERIA
  • Sponsors Takeda
  • Most Recent Events

    • 19 Dec 2018 Planned initiation date changed from 30 Nov 2018 to 16 Jan 2019.
    • 25 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top